SCHEMBL6351601

SCHEMBL6351601

CC(C)S(=O)(=O)NC1CCCCC1(F)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 3/20 0.39
LMNA P02545 2/20 0.39
NPY5R Q15761 1/20 0.38
MMP13 P45452 7/20 0.37
MMP2 P08253 6/20 0.37
MMP9 P14780 6/20 0.37
MMP14 P50281 4/20 0.37
MMP1 P03956 3/20 0.37
MMP3 P08254 2/20 0.37
MMP7 P09237 1/20 0.37
ADAM17 P78536 1/20 0.35
PGR P06401 1/20 0.34
FNTA P49354 1/20 0.33
FNTB P49356 1/20 0.33
EPHX1 P07099 1/20 0.33
MMP8 P22894 2/20 0.33
MEN1 O00255 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
RECQL P46063 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6410311 1.00 GRIA4 (0.39) GRIA4LMNANPY5RMMP13MMP2
SCHEMBL6351603 1.00 GRIA4 (0.39) GRIA4LMNANPY5RMMP13MMP2
SCHEMBL6349682 0.97 GRIA4 (0.40) GRIA4LMNANPY5RMMP13MMP2
SCHEMBL6342950 0.97 GRIA4 (0.40) GRIA4LMNANPY5RMMP13MMP2
SCHEMBL6342952 0.97 GRIA4 (0.40) GRIA4LMNANPY5RMMP13MMP2
SCHEMBL6354895 0.90 GRIA4 (0.45) GRIA4
SCHEMBL6354892 0.90 GRIA4 (0.45) GRIA4
SCHEMBL6348056 0.87 GRIA4 (0.41) GRIA4
SCHEMBL6353782 0.87 GRIA4 (0.41) GRIA4
SCHEMBL6348052 0.87 GRIA4 (0.41) GRIA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US claimed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US claimed
EP-1334087-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-08-13 EP claimed
WO-2002032858-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-04-25 WO claimed
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US disclosed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067984-A1 Cyclopentyl sulfonamide derivatives GRIN2A, GRIN1, GRIK5 GRIA4 15/4885LMNA 4826/4885NPY5R 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.